16. Earnings per share from continuing and discontinued operations
Earnings per share are determined according to IAS 33 (Earnings Per Share) by dividing net income by the weighted average number of shares.
Until June 1, 2009, the conversion date of the mandatory convertible bond issued in April 2006, the number of ordinary shares taken into account for this purpose included the potential shares that would be issued upon conversion of the bond. Basic and diluted earnings per share were therefore identical. The financing expenses for the mandatory convertible bond were added back to net income.
Following the conversion of the mandatory convertible bond, the number of ordinary shares in issue was 826,947,808.
Further details of the convertible bond can be found in Note [27].
| Earnings Per Share | [Table 4.41] | |
|---|---|---|
| 2008 | 2009 | |
| € million | € million | |
| Income after taxes | 1,724 | 1,359 |
| of which attributable to non-controlling interest | 5 | - |
| of which attributable to Bayer AG stockholders (net income) | 1,719 | 1,359 |
| Income from discontinued operations after taxes | 4 | - |
| Financing expenses for the mandatory convertible bond, net of tax effects | 112 | 47 |
| Adjusted net income from continuing operations | 1,827 | 1,406 |
| Adjusted net income from continuing and discontinued operations | 1,831 | 1,406 |
| Weighted average number of issued ordinary shares | 764,342,029 | 801,050,237 |
| (Potential) shares (to be) issued upon conversion of the mandatory convertible bond | 59,893,122 | 24,955,936 |
| Adjusted weighted average total number of issued and potential ordinary shares | 824,235,151 | 826,006,173 |
| Basic earnings per share | ||
| from continuing operations | 2.22 | 1.70 |
| from discontinued operations | - | - |
| from continuing and discontinued operations | 2.22 | 1.70 |
| Diluted earnings per share | ||
| from continuing operations | 2.22 | 1.70 |
| from discontinued operations | - | - |
| from continuing and discontinued operations | 2.22 | 1.70 |



Overview
Notes to the Consolidated Financial Statements of the Bayer Group
Bayer Links
Investor Relations


Advanced Search



